Drugs · acquisition-cost intelligence
Buprenorphine and Naloxone Sublingual Film
buprenorphine and naloxone· ingredient buprenorphineAntidotes· BUPRENORPHINE HYDROCHLORIDE 12 mg/1; NALOXONE HYDROCHLORIDE 3 mg/1; BUPRENORPHINE HYDROCHLORIDE 12 mg/1; NALOXONE HYDROCHLORIDE DIHYDRATE 3 mg/1; BUPRENORPHINE HYDROCHLORIDE 2 mg/1; NALOXONE .5 mg/1; BUPRENORPHINE HYDROCHLORIDE 2 mg/1; NALOXONE HYDROCHLORIDE .5 mg/1
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per EA
$2.26
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per EA — the trend nobody else shows. 6 weeks.
2025-12-172026-05-20
Same-ingredient options by acquisition cost
Other buprenorphine products, cheapest acquisition cost first. Per EA — confirm strength/form equivalence before switching.
| Product | NADAC / EA | vs this |
|---|---|---|
| Buprenorphine | $0.41449 | −$1.84 |
| Buprenorphine and Naloxone | $0.55472 | −$1.70 |
| Buprenorphine and Naloxone | $3.25 | +$0.99050 |
| buprenorphine transdermal system | $44.86 | +$42.60 |
Medicare Part D coverage · CY2026
On 318 plan formularies · typical tier 4
Prior auth 0% · Step therapy 0% · Quantity limit 52% of formularies
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.